
    
      This was a double-blind, placebo-controlled, randomized, multicenter Phase IIIb study of
      palifermin given before and after dose chemotherapy (total 6 doses) or before dose
      chemotherapy only (total 3 doses), in subjects with Multiple Myeloma (MM)receiving high dose
      melphalan (chemotherapy), in a 1-day schedule, followed by autologous Peripheral Blood Stem
      Cell Transplantation (PBSCT).

      All subjects were to be followed for disease progression, second primary tumors, additional
      malignancies and survival for up to 10 years.

      Planned: 275 subjects, in fact, 281 subjects were randomized. Randomized: 115 subjects to
      palifermin pre/post-CT, 109 subjects to palifermin pre-CT and 57 subjects to placebo
      Analyzed: 281 subjects in the full analysis set, 277 subjects in the safety subset.

      Efficacy Oral cavity assessment, patient reported outcome (PRO) questionnaires (Oral
      Mucositis Daily Questionnaire [OMDQ], Functional Assessment of Cancer Therapy Esophageal
      [FACT-E], European Quality of Life Utility Scale [EQ 5D], Mucositis Chronic Symptoms
      Questionnaire [MCSQ]).

      Safety Physical examination (including body temperature), concomitant medications,
      transfusions, vital signs, laboratory assessments (hematology, chemistry), cataract
      assessments, adverse events (AEs).
    
  